<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01504178</url>
  </required_header>
  <id_info>
    <org_study_id>09 303 03</org_study_id>
    <nct_id>NCT01504178</nct_id>
  </id_info>
  <brief_title>Evaluation of the Role of the Noradrenergic System in Pain Perception in Parkinson's Disease</brief_title>
  <acronym>DOULOX</acronym>
  <official_title>Evaluation of the Role of the Noradrenergic System in Pain Perception in Parkinson's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Toulouse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>French Parkinson Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Toulouse</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients suffering from Parkinson's disease (PD) frequently experienced painful sensations
      that could be, in part, due to a central modification of nociception mechanisms. Previous
      studies have shown that pain perception was altered in Parkinson's disease (subjective and
      objective pain thresholds and pain-induced cerebral activity) and that administration of
      L-Dopa normalized this alteration. In the central nervous system, L-Dopa is converted in
      dopamine and in norepinephrine. Apomorphine (a dopamine agonist) has no effect on pain
      threshold and pain-induced cerebral activity. Therefore the noradrenergic system could be
      involved in pain alteration in PD.

      To assess the role of noradrenergic system in pain in patients with PD, we chose duloxetine
      (norepinephrine and serotonin reuptake inhibitor)because a recent study had shown that
      duloxetine allowed an improvement of pain clinical scores (pain questionnaires) in patients
      with PD.

      36 patients will be enrolled in this study. We supposed that a chronic intake of duloxetine
      increase the pain perception level compare to the placebo. This increase would be the same
      than those observed with L-Dopa.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Subjective pain threshold determined using thermal stimulations (thermotest) with the method of levels</measure>
    <time_frame>One month</time_frame>
    <description>Before duloxetine intake and after one month of chronic duloxetine intake</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective pain threshold determined recording the nociceptive reflex of flexion</measure>
    <time_frame>One month</time_frame>
    <description>Before duloxetine intake and after one month of chronic duloxetine intake</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical evaluation of the severity of the motor handicap of patients using the Unified Parkinson's Disease Rating Scale (UPDRS III)</measure>
    <time_frame>One month</time_frame>
    <description>Before duloxetine intake and after one month of chronic duloxetine intake</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>duloxetine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The first group (12 patients) will receive, after 28 days of duloxetine treatment, one duloxetine dose, an injection of apomorphine and a placebo of L-Dopa.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>positive control (L-Dopa)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The second group (12 patients) will receive, after 28 days of placebo treatment, one placebo dose of duloxetine, an injection of apomorphine and injection of placebo of L-Dopa.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>negative control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The third group will receive, after 28 days of placebo treatment, one placebo of duloxetine, an injection of placebo of apomorphine and a dose of L-Dopa.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>duloxetine</intervention_name>
    <description>administration during 28 days</description>
    <arm_group_label>duloxetine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo of duloxetine</intervention_name>
    <description>administration during 28 days</description>
    <arm_group_label>positive control (L-Dopa)</arm_group_label>
    <arm_group_label>negative control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>injection of apomorphine</intervention_name>
    <description>injection performed at D28</description>
    <arm_group_label>duloxetine</arm_group_label>
    <arm_group_label>positive control (L-Dopa)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>injection of placebo of apomorphine</intervention_name>
    <description>performed at D28</description>
    <arm_group_label>negative control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>L-Dopa</intervention_name>
    <description>performed at D28</description>
    <arm_group_label>negative control</arm_group_label>
    <other_name>injection of L-dopa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>injection of placebo of L-Dopa</intervention_name>
    <description>performed at D28</description>
    <arm_group_label>duloxetine</arm_group_label>
    <arm_group_label>positive control (L-Dopa)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with clinical diagnosis of Parkinson's disease according to the criteria of
             the UKPDSBB

          -  Parkinson's disease patients with a score ≤ 3 on the Hoehn and Yahr scale

          -  Patients treated with dopaminergic antiparkinsonian drugs (L-Dopa, dopamine agonists,
             ICOMT…)

          -  Patients affiliated to a social protection program

          -  Women with efficacy contraception

        Exclusion Criteria:

          -  Patients suffering from another pathology causing chronic pain (rheumatic disease,
             traumatic or orthopedic pathologies…)

          -  Parkinson's disease patients with a score &gt; 3 on the Hoehn and Yahr scale

          -  Depressed patients (MADRS score &lt; 16)

          -  Patients suffering from a cancer

          -  Patients under tutelage, curatella or law protection

          -  Patients with a complete contraindication against apomorphine injections or duloxetine
             administration (selective serotonin reuptake inhibitor and monoamine oxydase
             inhibitors)

          -  Patients without any control of their arterial hypertension

          -  Patients with a neuroleptic treatment

          -  Pregnant women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christine Brefel-Courbon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Purpan hospital, Toulouse</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CIC, Purpan Hospital</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 30, 2011</study_first_submitted>
  <study_first_submitted_qc>January 2, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 5, 2012</study_first_posted>
  <last_update_submitted>February 21, 2017</last_update_submitted>
  <last_update_submitted_qc>February 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Noradrenergic system and pain in Parkinson's disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Duloxetine Hydrochloride</mesh_term>
    <mesh_term>Dihydroxyphenylalanine</mesh_term>
    <mesh_term>Levodopa</mesh_term>
    <mesh_term>Apomorphine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

